A Buyout for Manager of Drug Trials
319293
One Equity Partners agreed to sell its stake in Quintiles Transnational, a big manager of clinical drug trials, to its CEO and two buyout firms.
351992
In the latest endorsement of a science technique discovered at the University of Massachusetts, the international drug giant Roche signed a $331 million deal with Alnylam Pharmaceuticals Inc. of Cambridge for the rights to develop drugs using RNA interference.
594254
Bain and TPG announced they will acquire One Equityâs stake in Quintiles Transnational, one of the biggest managers of drug trials, for an undisclosed amount.
85851
Pfizer Inc , the world's largest drug maker, said on Friday it is in talks with investors about spinning off its Japanese research and development laboratory, albeit as a much smaller organization.
219400
The former will take over development of the latter's drug.
355967
OXiGENE reaches a deal with FDA on its lead compound.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
181860
Platforms have the potential to develop multiple drugs for a company.
699521
Management leads a $4.7 billion buyout bid. Are other bids on the way?
666716
The billionaire financier Carl C. Icahn offered yesterday to buy the generic drug maker Mylan Laboratories for about $5.4 billion in an effort to force Mylan to drop its proposed acquisition of King Pharmaceuticals.
748640
Analysts said the venture would create a drug benefit manager that could take on retail leader Wal-Mart
492811
In a management shake-up at Marlborough drug maker Sepracor Inc. , the company said in a regulatory filing it has hired Adrian Adams as president and chief operating officer and plans to promote him to chief executive within six months. Current president William James O'Shea will get a $1 million severance package and serve as vice chairman until ...
767331
Biopharma firm ends trials for a promising drug and offloads four commercial products.
15160
The Swiss pharmaceutical company Roche Holding said its chief executive would step down next March as the company separates that job from the chairmanâs position. Franz B. Humer, who has been chief since 1998, will remain chairman of the board. Next July, he also will become chairman of the beverage company Diageo. He will be succeeded by Severin Schwan, 40, who had been the head of Rocheâs diagnostics unit since January. The company also posted a 24 percent increase in first-half net profit, to 4.92 billion Swiss francs ($4.1 billion) from 3.97 billion francs in the period a year earlier. Roche benefited from its flu treatment Tamiflu as governments stockpile the drug in case of an influenza pandemic.
227772
The pharmaceutical sells European rights to a promising asthma drug.
115767
Will the pharmacy-benefits manager risk its own health by buying diabetes-testing supplier Polymedica?
71950
Schering-Plough Corp  has agreed to buy Akzo Nobel NV's  drugs unit Organon BioSciences for 11 billion euros ($14.4 billion) in a bid to gain scale and diversify away from cholesterol medicine.